Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Dusseldorf - Delayed Quote • EUR Teva Pharmaceutical Industries Ltd (TEV.DU) Follow Compare 11.80 +0.35 +(3.06%) At close: April 14 at 8:10:36 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for TEV.DU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: TEV.DU View More All News Press Releases SEC Filings 5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention Teva announces presentation of survey study on TEV-‘749 Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts? New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025